# Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma

> **NCT03486067** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 183 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-93269

## Key facts

- **NCT ID:** NCT03486067
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-03
- **Primary completion:** 2025-03-18
- **Final completion:** 2025-03-18
- **Target enrollment:** 183 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03486067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03486067, "Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03486067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*